Inqovi (decitabine-cedazuridine)

Numéro de dossier de l’APP: 21608
État des négociations:
Under consideration for negotiation
Inqovi (decitabine and cedazuridine) is indicated for treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System (IPSS) groups
Taiho Pharma Canada, Inc.
Numéro de projet de l’ACMTS:
Lettre-contrat de l’APP:
Not Applicable
Conclusion du processus de négociation:
Not Applicable